Alcon cuts 2024 forecasts, as slow US hits surgical unit
By Amir Orusov
Nov 13 (Reuters) -Eye-care group Alcon ALCC.S cut its 2024 forecasts and missed market expectations for third-quarter sales on Tuesday evening, as a soft U.S. market hit its surgical business.
Alcon, whose biggest market is the U.S. making up nearly a half of its revenue, said it expected annual net sales to grow by 6-7% in constant currency terms, compared to the previous forecast of 7-9%.
It sees 2024 core diluted earnings per share of between $3.00 and $3.05, bringing the top of the range down from $3.10.
The Swiss-American group posted a 6% rise in its third-quarter sales to $2.43 billion, but missed analysts' average forecast by 1.4%, according to LSEG data.
Slower market conditions in the U.S. impacted the surgical division, which posted a slower than expected 5% rise in sales, versus a consensus of 7.6% cited by J.P.Morgan in a research note.
Alcon also saw headwinds in its vision care division due to declines in contact lens care in its international markets. The unit posted 7% sales growth, below a consensus of 8.5%.
The company's New York-listed shares ALC.N closed 5.8% lower on Tuesday.
Ryan Zimmerman, an analyst at BTIG, said that while Alcon had been pointing to softer U.S. market dynamics for a while, their extent was proving more significant than anticipated.
"That said, we continue to look to full-year 2025 for a number of new products that are likely to boost growth," Zimmerman added.
Alcon, spun off from Novartis NOVN.S in 2019, is betting on new product launches to accelerate sales growth in 2025 and beyond.
Reporting by Amir Orusov in Gdansk; editing by Milla Nissi
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
